Madrigal Pharmaceuticals Inc (MDGL)
215.99
+5.91
(+2.81%)
USD |
NASDAQ |
May 02, 16:00
215.99
0.00 (0.00%)
After-Hours: 18:30
Madrigal Pharmaceuticals Cash from Operations (TTM): -324.23M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -324.23M |
September 30, 2023 | -302.81M |
June 30, 2023 | -276.96M |
March 31, 2023 | -259.01M |
December 31, 2022 | -224.86M |
September 30, 2022 | -214.39M |
June 30, 2022 | -200.88M |
March 31, 2022 | -190.40M |
December 31, 2021 | -183.92M |
September 30, 2021 | -190.81M |
June 30, 2021 | -193.11M |
March 31, 2021 | -170.48M |
December 31, 2020 | -157.56M |
September 30, 2020 | -114.90M |
June 30, 2020 | -78.37M |
March 31, 2020 | -65.65M |
December 31, 2019 | -41.62M |
September 30, 2019 | -35.61M |
June 30, 2019 | -29.52M |
March 31, 2019 | -23.34M |
December 31, 2018 | -25.51M |
September 30, 2018 | -25.19M |
June 30, 2018 | -24.90M |
March 31, 2018 | -27.19M |
December 31, 2017 | -22.32M |
Date | Value |
---|---|
September 30, 2017 | -21.65M |
June 30, 2017 | -25.94M |
March 31, 2017 | -20.94M |
December 31, 2016 | -17.61M |
September 30, 2016 | -13.42M |
June 30, 2016 | 30.28M |
March 31, 2016 | 15.20M |
December 31, 2015 | -3.142M |
September 30, 2015 | -21.26M |
June 30, 2015 | -74.29M |
March 31, 2015 | -77.43M |
December 31, 2014 | -78.92M |
September 30, 2014 | -78.40M |
June 30, 2014 | -76.42M |
March 31, 2014 | -75.47M |
December 31, 2013 | -77.41M |
September 30, 2013 | -71.24M |
June 30, 2013 | -67.92M |
March 31, 2013 | -61.10M |
December 31, 2012 | -54.14M |
September 30, 2012 | -52.10M |
June 30, 2012 | -50.66M |
March 31, 2012 | -49.72M |
December 31, 2011 | -47.30M |
September 30, 2011 | -45.03M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-324.23M
Minimum
Dec 2023
-29.52M
Maximum
Jun 2019
-171.32M
Average
-190.40M
Median
Mar 2022
Cash from Operations (TTM) Benchmarks
Eli Lilly and Co | 3.676B |
Viking Therapeutics Inc | -54.87M |
Akero Therapeutics Inc | -145.37M |
89bio Inc | -129.19M |
Geron Corp | -167.74M |